High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

Inclusion Criteria: * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent * Men or women \> 18 years of age at the time of signing the Informed Consent Form * Diagnosed with type 1 or type 2 diabetes mellitus * BCVA ETDRS \>/= 20/400 in the study eye * Any Proliferative Diabetic Retinopathy as diagnosed via clinical examination and fluorescein angiography Exclusion Criteria: * Any known hypersensitivity to any of the components of aflibercept 8 mg injection * Any known hypersensitivity to any contrast media (e.g., fluorescein), dilating eye drops, disinfectants (e.g., iodine), or any of the anesthetics and antimicrobial preparations used bye the site during the study * Prior systemic anti-VEGF or IVT anti-VEGF treatment in the study eye within 3 months of enrollment. (i.e., 3-month (90 days) wash-out period for anti-VEGF allowed) * Any intra- or periocular corticosteroid treatment in the study eye within 3 months (90 days) of baseline * Any intraocular sustained-release treatment or implantable device in the study eye * Any gene therapy in the study eye * SD-OCT central subfield thickness measurement of \> 320 µm, in the study eye * Evidence of ocular infection, in the study eye, at time of screening * IOP \>/= 25 mmHg in the study eye * Any intraocular inflammation/ infection in either eye within 12 weeks (84 days) of the screening visit * History of vitreoretinal surgery in the study eye * Any prior Panretinal lase…